iOrganBio

iOrganBio is a Chapel Hill, North Carolina biotechnology company developing CellForge, a platform it describes as the first AI-powered system for scalable and reproducible human cell and organoid engineering. The platform combines predictive machine learning with high-throughput experimental control to automate and optimize the development of human cells for drug discovery, regenerative medicine and cell therapy production. At its core is the trademarked Functional Human CellAtlas, a repository of single-cell RNA sequencing and other multi-omics data that serves as a digital reference for defining target cell types and states.

CellForge applies closed-loop AI control to 3D culture systems, dynamically adjusting culture conditions during human pluripotent stem cell (hPSC) differentiation to reach defined biological profiles in real time. The company states the approach supports cell types derived from stem cells and peripheral blood cells, and addresses five design goals: definability, generalizability, adaptability, reproducibility and scalability. Reported early results include the identification of specific beta islet cells used to guide organoid and tissue design, enabling pancreas models with tailored properties such as optional vasculature and immune competency for disease modeling, drug testing and regenerative applications.

The company positions its technology as a way to reduce variability and cost in cell-based research and therapeutic manufacturing, with stated goals that include supporting therapeutic development that bypasses animal testing and enabling cell-based lab tests matched to individual patients.